Clinical Context
Gestational diabetes mellitus (GDM) affects 6-9% of pregnancies globally and is associated with significant maternal and fetal complications. Poor glycemic control during pregnancy increases risks of fetal macrosomia, birth trauma, neonatal hypoglycemia, respiratory distress syndrome, and long-term metabolic programming effects in offspring. For mothers, GDM increases cesarean delivery rates and substantially elevates lifetime risk of developing type 2 diabetes.
Traditional management relies on self-monitoring of blood glucose (SMBG) with fingerstick testing, typically 4-7 times daily. However, SMBG captures only snapshots of glucose levels, missing postprandial excursions, nocturnal variations, and the overall glycemic pattern. Many women with GDM have glucose values that appear acceptable on spot checks yet experience significant hyperglycemia between measurements.
Continuous glucose monitoring (CGM) technology has revolutionized diabetes management in type 1 and type 2 diabetes, but its role in GDM has been less established. CGM provides near-continuous glucose data (readings every 5-15 minutes), trend information, and alerts for impending hypo- or hyperglycemia. This study (DipGluMo) examined whether CGM improves outcomes in GDM compared to standard fingerstick monitoring.
Study Summary (PICO Framework)
Summary:
In pregnant women with gestational diabetes mellitus (GDM), continuous glucose monitoring (CGM) significantly improved glycemic control and pregnancy outcomes compared to self-monitoring of blood glucose (SMBG), though it was associated with increased device usage burden and mild skin irritation.
| PICO | Description |
|---|---|
| Population | Pregnant women diagnosed with gestational diabetes mellitus (GDM) in Switzerland. |
| Intervention | Continuous glucose monitoring (CGM) used throughout pregnancy for glycemic management. |
| Comparison | Standard self-monitoring of blood glucose (SMBG) as usual care. |
| Outcome | CGM led to better glycemic control, reduced fetal macrosomia, and improved neonatal outcomes. Side effects included mild skin irritation and device burden. |
Clinical Pearls
1. CGM reveals hidden hyperglycemia that SMBG misses. Women with GDM may have acceptable fasting and pre-meal glucose values yet experience significant postprandial spikes lasting 1-2 hours. CGM captures these excursions, enabling targeted dietary modifications or medication adjustments that would not be prompted by normal fingerstick results.
2. Reduced macrosomia has downstream benefits. Large-for-gestational-age (LGA) infants face increased risk of shoulder dystocia, birth injury, and cesarean delivery. The reduction in macrosomia with CGM translates into safer deliveries and potentially fewer cesarean sections—benefits that extend beyond glucose numbers to tangible clinical outcomes.
3. CGM empowers patient self-management. Real-time glucose feedback allows women to immediately see the impact of food choices, portion sizes, and physical activity. This biofeedback accelerates learning and promotes sustained dietary adherence better than delayed fingerstick results can achieve.
4. Device burden and skin irritation are manageable concerns. Modern CGM sensors are smaller and more comfortable than earlier generations. Skin irritation can be minimized with proper site rotation and barrier products. Most women adapt to device wear within the first week, and the information gained typically outweighs the inconvenience.
Practical Application
Patient selection for CGM in GDM: Consider CGM for women with GDM who have suboptimal control despite dietary management, require insulin therapy, have difficulty achieving target glucose values, or express interest in more detailed glucose information. CGM may also benefit women with prior GDM and adverse outcomes who are highly motivated to optimize this pregnancy.
CGM initiation and education: Provide hands-on training for sensor insertion and app/reader use. Explain that the first 24 hours may show inaccurate readings during sensor “warm-up.” Teach interpretation of trend arrows (rising, falling, stable) and appropriate responses. Set realistic expectations that CGM reveals more glucose variability than expected—this is information, not failure.
Target glucose ranges in GDM: Typical CGM targets for GDM include fasting glucose <95 mg/dL (5.3 mmol/L), 1-hour postprandial <140 mg/dL (7.8 mmol/L), and 2-hour postprandial 70% time in the 63-140 mg/dL range.
Insurance and cost considerations: CGM coverage for GDM varies by payer and region. Some insurers cover CGM only for insulin-requiring GDM. The cost of sensors (approximately $75-150 per 10-14 day sensor without insurance) may be a barrier. However, if CGM use prevents one NICU admission or cesarean delivery, it is highly cost-effective.
How This Study Fits Into the Broader Evidence
The CONCEPTT trial (2017) demonstrated CGM benefits in pregnant women with type 1 diabetes, showing reduced LGA births and neonatal complications. This DipGluMo study extends similar findings to GDM, where the evidence base has been less robust.
The ADA Standards of Care 2025 acknowledge CGM as an option for GDM management, particularly for women on insulin therapy. However, routine CGM for all GDM is not yet universally recommended due to cost and limited outcomes data—a gap this study helps address.
Real-world implementation studies have shown that intermittently scanned CGM (FreeStyle Libre) is more commonly used in pregnancy than real-time CGM (Dexcom) due to lower cost and simpler use, though both provide substantial advantages over SMBG alone.
Limitations to Consider
This was a single-center study in Switzerland, which may limit generalizability to other healthcare systems. The open-label design means participants knew their treatment assignment, potentially introducing bias in self-management behaviors. Long-term offspring outcomes were not assessed. Additionally, the specific CGM system used may influence results, as sensor accuracy varies between devices.
Bottom Line
Continuous glucose monitoring improves glycemic control and reduces adverse pregnancy outcomes in gestational diabetes compared to traditional fingerstick monitoring. For women with GDM, particularly those requiring insulin or struggling to achieve glucose targets, CGM provides actionable insights that translate into healthier pregnancies. The device burden and skin irritation are minor drawbacks compared to the benefits of improved maternal and neonatal outcomes.
Source: Amylidi-Mohr, Sofia, et al. “Continuous Glucose Monitoring in the Management of Gestational Diabetes in Switzerland (DipGluMo): An Open-Label, Single-Centre, Randomized, Controlled Trial.” Read article here.
